You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The startup has developed a platform that allows precise engineering of optical properties to provide high-resolution analysis of single cells by high throughput flow cytometry.
The Irvine, California-based firm said its "Revolution" system offer recovery rates of 70 to 90 percent across a wide range of liquid sample volumes.
The firm will use the funding to build a high-throughput flow cytometry system that sorts cells based on high-content 3D features.
The Boston-based company is working to make its extracellular vesicle detection technology more widely available for research and biomarker discovery.
The firm said CRISPR will enable targeted sequencing of long regions of interest that were previously only accessible with long-read whole-genome sequencing.
10x CEO and Cofounder Serge Saxonov reflected on how the firm's IPO got so big and how he plans to make the single-cell analysis firm even bigger.
The Pleasanton, California-based single-cell sequencing firm said that net proceeds of the IPO will be approximately $357.5 million.
The new method may be useful in future noninvasive prenatal tests that rely on the analysis of DNA from fetal cells instead of cell-free fetal DNA.
The company believes that Xdrop will find adopters in academia and clinical research, although diagnostics is on its radar.
Spurred to develop new microfluidic chip technology, 10x told customers not to worry about the transition but told a court there would be "guaranteed hitches."
The SuperExtract 32 with the SuperExtract Viral Mag NA Purification kit provides high-quality purification of hepatitis and HIV viral nucleic acid.
The company provided updates on its newborn screening testing presence.
Researchers have launched a startup called Fluxus to commercialize a platform based on the optofluidic chip for molecular analysis.
In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.
Researchers developed a microfluidic device that combines antibody-based cell capture and disulfide cleavage for downstream microRNA detection.
The firm will begin a verification study later this month using its cell-sorting platform and molecular analysis tool on patients with a pelvic mass scheduled for surgery.
The Methyl-HiC assay, which combines epigenetic and genome structure analyses, comes from a lab with a history of commercializing tests.
X Gen US, a California startup led by a veteran sequencing tools developer, says its kits can create single-cell RNA-seq libraries in less than two hours.
The exact restrictions the injunction will place on 10x are not yet determined. 10x will also have to pay Bio-Rad additional damages, plus interest.
Following a South Korean distribution agreement signed in May, the deal further expands the reach of NanoCellect's microfluidic-based cell handling products.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.